Is Mammogram an essential investigation for detecting breast cancer in patients younger than 40 years?  by Williams, Annabelle et al.
Abstracts / International Journal of Surgery 10 (2012) S1–S52S10
ABSTRACTStrust therefore only an additional cost of £10,000 per year would be
required for a dedicated anaesthetist.
0383: ARE THE NUMBER OF LYMPH NODES EXCISED DURING AXILLARY
NODE CLEARANCE SURGERY AFFECTED BY NEOADJUVANT
CHEMOTHERAPY?
David Naumann, Martin Sintler. Sandwell and West Birmingham Hospitals
NHS Trust, West Midlands, UK
Introduction: Neoadjuvant chemotherapy may change the macroscopic
architecture of lymph nodes (LNs) to such a degree that the number
counted by a histologist following axillary node clearance (ANC) is lower
than expected by the surgeon. We test the hypothesis that chemotherapy
prior to ANC reduces the number of LNs.
Methods: Retrospective study examining records for all patients under-
going ANC at a NHS Trust over a 17 month period. We compared the
number of LNs counted on histological examination between the patient
groups who had received neoadjuvant chemotherapy and those who had
not, with further subdivision into groups who had undergone sentinel
node biopsy (SNB) prior to ANC and those who had not.
Results: There were 237 ANC operations including 98 ANC alone, 36 ANC
following chemotherapy but no SNB, 61 ANC following SNB but no
chemotherapy, and 42 following both SNB and chemotherapy, yielding
14.4 (6.5), 13.0 (5.8), 14.3 (5.1), and 15.1 (5.5) mean LNs respectively
(p ¼ 0.398).
Conclusion:We ﬁnd no statistically signiﬁcant difference in the number of
LNs from excised axillary tissues between patients who received neo-
adjuvant chemotherapy and those who had not. Lower than expected
number of LNs may not credibly be attributed to neoadjuvant chemo-
therapy.
0387: BLUE DYE DIRECTED AXILLARY NODE SAMPLING- REVISITING
THE ROLE
Rachel French, Vijay Kurup. University Hospital North Tees, Stockton-on-
Tees, UK
Aim: To evaluate whether combination of Sentinel Lymph Node Bio-
psy(SLNB) using patent blue dye and four node sampling as a reasonable
alternative to SLNB (dual technique), in early breast cancer as guidelines
recommend.
Methods: A retrospective study of SLNB using patent blue dye and four
nodes sampling performed by a single surgeon from 2006-'11. All
245patients treated byWLE were included. SLN were localised by injecting
2 ml patent blue dye in the subareolar with further Level 1 sampling done
to achieve a minimum of 4 nodes, by palpation. Node positive axillae were
treated by radiotherapy or clearance as per MDT decision.
Results: The detection rate was 97.95% (240/245 patients). 41 patients had
axillary metastases- 38 cases SLN positive and 3 Negative. False negative
rate 1.5%, Sensitivity 92.7% and negative predictive value 98.5%. 21/
41patients (51.2%) had only one node involved in their axilla. Axillary
morbidity was minimal and recurrence nil at 5 years.
Conclusion: Injection technique and experience of surgeon can lead up to
98% SLN detection using blue dye alone with comparable false negativity.
Combining with four node sampling reduces the impact of false negativity
and avoids unnecessary axillary clearance in single node disease (51.2%).
0432: TRIPLE NEGATIVE BREAST CANCER; BACKGROUND, TREATMENT
AND FUTURE OPTIONS
Rebecca Watts-Cherry 1, Eleri Davies 2. 1Cardiff University, Cardiff, UK;
2 Llandough Hospital, Cardiff, UK
Aims: Identify a subgroup of patients who were diagnosed with triple
negative breast cancer (TNBC) in Cardiff and Vale (CAV) in 2006-2011, to
enable an understanding of how TNBC patients present, what treatment is
given and which patients had recurrences.
Method: This was a retrospective study. The pathology database gave a list
of TNBC patients. Using this information, the Clinical Portal and CANNISC
databases allowed the proforma to be completed, which was then ana-
lysed. All people diagnosed as having TNBC in CAV in 2006 - 2011 were
included. No age or gender restriction was imposed.
Results: 101 patients were included in the study, of these 77 (76%) are alive
up to 5 years after. 11 (11%) developed recurrences and 7 (7%) developedmetastasis. Of these 86% had grade 3 tumours (study average(sa)¼79%),
86% had invasive ductal carcinoma (sa¼ 87%) and the average size was
54mm (sa¼ 33mm). 67 (66%) patients received chemotherapy which was
found to enhance survival (p¼0.003).
Conclusion: TNBC disease is very responsive to chemotherapy agents, so
must be given to all triple-negative patients as routine treatment irre-
spective to the histological result. The results obtained compare appro-
priately with the majority of studies already conducted.
0438: DIFFERENCES IN PATIENT EXPERIENCE AND UNDERSTANDING OF
CONSENT WHEN CARRIED OUT IN CLINIC AND ON THE DAY OF
SURGERY
Amy Lord, Shehryer Naqvi, Ramesh Babu, Richard Sainsbury. St Mary's
Hospital, Isle of Wight, UK
Aims: To assess patients’ subjective perception of consent and recall of
information when comparing those consented in clinic with those con-
sented immediately before surgery.
Methods: Prospective study of patients undergoing breast and general
surgical operations. Patients were randomised to consent in clinic or
consent immediately before surgery. Patients completed a post-operative
questionnaire assessing satisfaction and recall of complications using
a tick-box list of 16 common complications, 6 of which were correct for
each operation. An overall score of correct minus incorrect answers was
calculated out of 6.
Results: 27 patients were included, 17 consented immediately pre-oper-
atively, and 10 in clinic (mean - 13 days pre-op). The mean overall score for
recollection of complications was 3 when consented on the day and 2.9
when consented in clinic. Subjective ratings of experience were not
signiﬁcantly different between the groups. Overall recall rates were better
for general complications (96% bleeding, 100% infection and 74% anaes-
thetic risk) than speciﬁc risks (25% seroma in breast patients).
Conclusions: In our experience patients can be consented either in clinic
or on the day of operation as there is no difference in their subjective
perceptions or recall of information. However only small numbers have
been assessed so far.
0457: IS MAMMOGRAM AN ESSENTIAL INVESTIGATION FOR DETECTING
BREAST CANCER IN PATIENTS YOUNGER THAN 40 YEARS?
Annabelle Williams, Rachel Hung, Yazan Masannat, Anil Desai, Prakash
Sinha. Princess Royal University Hospital, London, UK
Aims: Breast cancer is the commonest female cancer diagnosed in the UK.
In November 2010, the ‘Best Practice Diagnostic Guidelines for Patients
Presenting with Breast Symptoms' were amended. This study aims to
evaluate the safety of the proposed changes that statemammography is no
longer an essential ﬁrst line investigation for women under the age of 40,
with breast symptoms,
Methods: A retrospective cohort study of 40 patients, from January 2007
to July 2011, with histologically conﬁrmed breast cancer diagnosed when
under the age of 40 was performed by comparing mammography and
ultrasound results.
Results: All patients presented with a symptomatic lump and underwent
ultrasound scanning, mammography and core biopsy. No patient with
a normal ultrasound was found to have an abnormal mammogram. In all
40 patients ultrasound scanning showed 100% sensitivity in identifying the
breast lesions with 95% identiﬁed as indeterminate, suspicious or malig-
nant radiologically.
Conclusions: The new symptomatic breast guidelines are safe to imple-
ment, as ultrasound is an adequate ﬁrst line investigation. If any suspicious
ultrasound abnormality is detected then mammogram is essential for
further assessment as this could demonstrate further pathological changes
which may affect clinical management. This should lead to improved
patient care and resource management.
0471: BREAST PAIN UNDER THE AGE OF 50: IS MAMMOGRAPHY REALLY
NECESSARY?
R.E. Foulkes, R. Thomas, S. Ghosh. Nevill Hall Hospital, Abergavenny, UK
Aim: The aim of this study was to assess whether routine mammography
in patients presenting with painful breasts, and no palpable mass is
necessary in those under the age of 50 years.
